Evidence map›Paper›PMID 17616479›Full record

ArticleBiochimica et biophysica acta2007

Inhibition of sphingomyelin synthase (SMS) affects intracellular sphingomyelin accumulation and plasma membrane lipid organization.

Zhiqiang Li, Tiruneh K Hailemariam, Hongwen Zhou, Yan Li, Dale C Duckworth, David A Peake, Youyan Zhang, Ming-Shang Kuo, Guoqing Cao, Xian-Cheng Jiang

Open access · greenAbstract read
In one paragraph

Article in Biochimica et biophysica acta, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 124 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. SiScience · 2023
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Sphingolipids and Cholesterol.Advances in experimental medicine and biology · 2022
    Article
  15. Sphingomyelin Synthase Family and Phospholipase Cs.Advances in experimental medicine and biology · 2022
    Article
  16. Article
  17. Review
  18. Article
  19. S1P and plasmalogen derived fatty aldehydes in cellular signaling and functions.Biochimica et biophysica acta. Molecular and cell biology of lipids · 2020
    Review
  20. Article

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Zhiqiang LiDepartment of Anatomy and Cell Biology, State University of New York Downstate Medical Center, 450 Clarkson Ave. Box 5, Brooklyn, NY 11203, USA.
Tiruneh K Hailemariam
Hongwen Zhou
Yan Li
Dale C Duckworth
David A Peake
Youyan Zhang
Ming-Shang Kuo
Guoqing Cao
Xian-Cheng Jiang
Eli Lilly (United States) · USState University of New York · USSUNY Downstate Health Sciences University · US

Funding

The role of PLTP in BLp metabolism and atherogenesisR01HL069817 · NHLBI · SUNY DOWNSTATE MEDICAL CENTER · PI JIANG, XIAN-CHENG · 2002 to 2010
$2.6M
THE ROLE OF PLASMA SPHINGOMYELIN IN ATHEROSCLEROSISR01HL064735 · NHLBI · SUNY DOWNSTATE MEDICAL CENTER · PI JIANG, XIAN-CHENG · 2001 to 2004
$1.1M
NHLBI NIH HHS HL-64735NHLBI NIH HHS HL-69817NHLBI NIH HHS R01 HL064735NHLBI NIH HHS R01 HL069817
6 · The paper itself

Abstract

Sphingomyelin plays a very important role both in cell membrane formation that may well have an impact on the development of diseases like atherosclerosis and diabetes. However, the molecular mechanism that governs intracellular and plasma membrane SM levels is largely unknown. Recently, two isoforms of sphingomyelin synthase (SMS1 and SMS2), the last enzyme for SM de novo synthesis, have been cloned. We have hypothesized that SMS1 and SMS2 are the two most likely candidates responsible for the SM levels in the cells and on the plasma membrane. To test this hypothesis, cultured cells were treated with tricyclodecan-9-yl-xanthogenate (D609), an inhibitor of SMS, or with SMS1 and SMS2 siRNAs. Cells were then pulsed with [14C]-L-serine (a precursor of all sphingolipids). SMS activity and [14C]-SM in the cells were monitored. We found that SMS activity was significantly decreased in cells after D609 or SMS siRNA treatment, compared with controls. SMS inhibition by D609 or SMS siRNAs significantly decreased intracellular [14C]-SM levels. We measured cellular lipid levels, including SM, ceramide, phosphatidylcholine, and diacylglycerol and found that SMS1 and SMS2 siRNA treatment caused a significant decrease of SM levels (20% and 11%, respectively), compared to control siRNA treatment; SMS1 but not SMS2 siRNA treatment caused a significant increase of ceramide levels (10%). There was a decreasing tendency for diacylglycerol levels after both SMS1 and SMS2 siRNA treatment, however, it was not statistical significant. As shown by lipid rafts isolation and lipid determination, SMS1 and SMS2 siRNA treatment led to a decrease of SM content in detergent-resistant lipid rafts on the cell membrane. Furthermore, SMS1 and SMS2 siRNA-treated cells had a stronger resistance than did control siRNA-treated cells to lysenin (a protein that causes cell lysis due to its affinity for plasma membrane SM). These results indicate that both SMS1 and SMS2 contribute to SM de novo synthesis and control SM levels in the cells and on the cell membrane including plasma membrane, implying an important relationship between SMS activity and cell functions.

Indexed as

Cell MembraneMembrane LipidsAnimalsBridged-Ring CompoundsCell LineCeramidesHumansIsoenzymesMembrane MicrodomainsMembrane ProteinsNerve Tissue ProteinsNorbornanesPhosphodiesterase InhibitorsRNA, Small InterferingSphingomyelin PhosphodiesteraseSphingomyelinsBridged-Ring CompoundsCeramidesIsoenzymesMembrane LipidsMembrane ProteinsNerve Tissue ProteinsNorbornanesPhosphodiesterase InhibitorsRNA, Small InterferingSGMS1 protein, humanSphingomyelin PhosphodiesteraseSphingomyelinsThiocarbamatesThionesTransferases (Other Substituted Phosphate Groups)tricyclodecane-9-yl-xanthogenate

Identifiers

PMID17616479
PMCPMC2712822
OpenAlexW2069921134

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.